Intellia Therapeutics Inc (NASDAQ:NTLA) traded down 3.3% during trading on Monday . The company traded as low as $19.07 and last traded at $19.07, with a volume of 56,657 shares traded. The stock had previously closed at $19.72.

A number of equities research analysts recently commented on the company. Jefferies Group assumed coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They set a “hold” rating and a $33.00 price target on the stock. Zacks Investment Research upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Leerink Swann upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $32.00 price objective on the stock in a research report on Friday, August 5th. Wedbush began coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 price objective on the stock. Finally, Credit Suisse Group AG began coverage on Intellia Therapeutics in a research report on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Intellia Therapeutics presently has an average rating of “Buy” and an average price target of $35.50.

The stock’s market cap is $686.06 million. The company’s 50-day moving average price is $20.13 and its 200 day moving average price is $22.53.

Several large investors have recently added to or reduced their stakes in NTLA. FMR LLC acquired a new stake in Intellia Therapeutics during the second quarter worth $112,182,000. Temasek Holdings Private Ltd acquired a new stake in Intellia Therapeutics during the second quarter worth $16,878,000. BlackRock Advisors LLC acquired a new stake in Intellia Therapeutics during the second quarter worth $13,146,000. Vanguard Group Inc. acquired a new stake in Intellia Therapeutics during the second quarter worth $8,894,000. Finally, Franklin Resources Inc. acquired a new stake in Intellia Therapeutics during the second quarter worth $6,405,000.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

5 Day Chart for NASDAQ:NTLA

Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.